HOLX · United States
Financials as of FY2025
Sells diagnostic instruments to clinical labs, then earns recurring income from the test cartridges those instruments require.
What this company is and how it runs — written from structure, not news.
Hologic sells automated laboratory instruments — the Panther and Tigris platforms — into clinical laboratories that run daily STI screening tests, and then earns recurring revenue from the reagent cartridges those instruments consume with every test. The cartridges use a chemistry called TMA, which amplifies RNA rather than DNA, so a positive result proves an infection is actively replicating rather than leaving behind genetic debris from a past one — that clinical distinction got Aptima written into CDC-aligned screening protocols, which is what drove laboratories to adopt the instruments at scale in the first place. Because each Panther or Tigris platform is built around a specific fluidic architecture that only accepts Aptima cartridges, a laboratory that wants to switch to a competing test must first run months of validation studies to satisfy its CAP/CLIA accreditation requirements, which means the installed base stays captive not through contracts but through regulatory process. The same manufacturing concentration that makes the chemistry precise — TMA reagents must be produced under tightly controlled isothermal conditions and shipped cold from a small number of sites — means that a single failed batch or a regulatory hold on one production facility would stop reagent shipments to every installed instrument simultaneously, with no alternative cartridge that laboratories could legally substitute without completing that same months-long revalidation.
How does this company make money?
The largest revenue stream is per-test reagent sales: every time a Panther or Tigris platform in a clinical lab runs an Aptima STI test, the company sells the cartridge. The company also earns money upfront when it sells Panther, Tigris, and Genius 3D mammography capital equipment, and then collects ongoing service contract fees on those machines. Finally, it earns revenue each time a MyoSure device is used in a surgical procedure, since the device is single-use and must be replaced for every case.
What makes this company hard to replace?
A laboratory running Aptima tests on a Panther or Tigris platform must complete extensive validation studies and satisfy CAP/CLIA accreditation requirements before it can move to any different molecular method — a process that takes months and cannot be shortcut. A breast imaging center replacing a Genius 3D mammography system must modify facility radiation shielding and obtain new state health department licensing, which also creates a multi-month delay. A hospital using MyoSure devices must go through credentialing and surgeon training certification that is specific to MyoSure and does not transfer to a competing hysteroscopic system.
What limits this company?
The Aptima reagents have to stay cold and be made under tightly controlled conditions, which means production is concentrated in a small number of manufacturing sites. Those sites cannot easily hand off production to another location. If one site has a problem — a bad batch, a quality failure, a shutdown — every Panther and Tigris platform in the field runs out of cartridges at the same time, with no backup chemistry that fits those machines.
What does this company depend on?
The company cannot operate without FDA 510(k) clearances for each Aptima assay indication, because a clearance revocation would pull a test off the market entirely. It also depends on specialized isothermal amplification reagents that make TMA chemistry work, cleanroom manufacturing facilities certified to ISO 13485 medical device standards, cesium iodide scintillator materials used in its digital mammography detectors, and exclusive licensing agreements that cover specific molecular diagnostic targets.
Who depends on this company?
Clinical laboratories running Panther and Tigris platforms would lose their primary high-throughput method for detecting chlamydia, gonorrhea, and trichomonas if the company stopped supplying Aptima cartridges, and no drop-in replacement exists for those machines. Breast imaging centers using Genius 3D mammography systems would face equipment replacement costs and the need to retrain technologists to maintain tomosynthesis screening. Gynecologic surgeons who perform MyoSure procedures would have to learn different tissue removal techniques and work with different instruments.
How does this company scale?
Aptima reagent production scales well — automated liquid handling and batch chemistry mean that the cost of producing each individual test drops as total volume rises. Mammography system manufacturing does not scale the same way, because the detector arrays are hand-assembled and require complex calibration by specialized technicians, work that cannot be fully automated.
What external forces can significantly affect this company?
Medicare reimbursement rates for breast cancer screening directly affect how much hospitals are willing to spend on new mammography equipment. CDC surveillance guidelines on sexually transmitted infections can drive public health laboratories to adopt molecular testing, which expands demand for Aptima assays. In Europe, IVDR regulations now require additional clinical evidence for existing molecular diagnostic tests sold in EU markets, adding regulatory cost and timeline to products already on the market.
Where is this company structurally vulnerable?
If the FDA issued a manufacturing hold on the facility that produces TMA reagents — triggered by a sterility failure, an out-of-specification batch, or a quality system deficiency — reagent shipments would stop to every installed Panther and Tigris in the field. The same CAP/CLIA revalidation barrier that normally protects the installed base from voluntary switching would also prevent labs from quickly qualifying an emergency replacement, leaving them without functioning STI diagnostic capacity for however long the hold lasted.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph